Precision BioSciences

Precision BioSciences to Participate in Upcoming June Investor Conferences

Retrieved on: 
Donnerstag, Mai 30, 2024
Research, Technology, Genetics, Clinical Trials, Nanotechnology, Stem Cells, Biotechnology, Pharmaceutical, Health, Science, Precision BioSciences, Gene editing

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that members of management will participate in the following upcoming investor conferences in June:

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that members of management will participate in the following upcoming investor conferences in June:
    A live webcast of each presentation will also be accessible on Precision’s website in the Investors section under Events & Presentations at investor.precisionbiosciences.com .
  • An archived replay of the webcasts will be available for approximately 30 days following each event.

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Freitag, Mai 17, 2024
Research, Technology, Genetics, Health Technology, Software, Other Health, Biotechnology, Health, Science, Other Science, Employment, Precision, Common stock, Precision BioSciences, Gene editing, Compensated emancipation

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on May 13, 2024, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”).

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on May 13, 2024, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”).
  • Each award was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for the employees to commence service with Precision.
  • The stock option has a per share exercise price equal to the fair market value of Precision’s Common Stock on May 13, 2024, which was equal to $11.50.
  • Each employee’s RSUs vest (subject to continued service to Precision through the applicable vesting dates) in substantially equal annual installments on each of the first three anniversaries of the date of the commencement of such individual’s employment.

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Montag, Mai 13, 2024
Science, Biometrics, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Janus, CTA, Novartis, Autoimmune disease, Sickle cell disease, IND, Hemoglobinopathy, OTC, Primate, Neuron, Fast Track, Vivo, RNA, CRISPR, Therapy, TRAC, Gene editing, Cell, Patent, NHP, Hepatitis B virus, HBV, Mitochondrion, ATM, Administration, CccDNA, PMM, Infant, Economics, Precision BioSciences, Rachel Haurwitz, Food, AAV, Duchenne muscular dystrophy, Cancer, Mitochondrial disease, Nature Metabolism, Precision, Patient, DNA, University, Gene, Cash, Development, Central nervous system, Pharmaceutical industry

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update.
  • PBGENE-HBV is advancing through final toxicology studies and Precision expects to submit an IND and/or CTA for this program in 2024.
  • Cash and Cash Equivalents: As of March 31, 2024, Precision had approximately $137.8 million in cash and cash equivalents.
  • Shares: Basic weighted-average common shares outstanding for the first quarter of 2024 were 5,060,978 compared to 3,709,894 for the same period in 2023.

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement

Retrieved on: 
Mittwoch, Mai 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Genetics, Clinical Trials, Private placement, Sale, Private, Precision BioSciences, Gene editing, News, Security (finance)

The Private Placement is expected to close on May 8, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The Private Placement is expected to close on May 8, 2024, subject to the satisfaction of customary closing conditions.
  • The Company intends to use the net proceeds from this offering to support its ongoing research and development initiatives.
  • There is no placement agent for the Private Placement.
  • The offer and sale of the securities have not been, and will not be, registered under the Securities Act of 1933, as amended, or any other securities laws.

Precision BioSciences to Report First Quarter Results on May 13, 2024

Retrieved on: 
Dienstag, Mai 7, 2024
FDA, Other Health, Technology, Nanotechnology, Stem Cells, Pharmaceutical, Infectious Diseases, Genetics, Fitness & Nutrition, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Gene editing, Precision BioSciences

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024.

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

Retrieved on: 
Dienstag, Mai 7, 2024
Research, Medical Devices, FDA, Genetics, Health Technology, Biotechnology, Health, Other Science, Science, CTA, Fast Track, Safety, Pharmacokinetics, Food, European Commission, OTC, Gene editing, Communication, Collection, IND, Therapy, Precision BioSciences, Patient, Civil service commission, Standard of care, Precision, Vaccine

ECUR-506 is iECURE’s in vivo gene insertion program designed to treat neonatal onset Ornithine Transcarbamylase (OTC) deficiency utilizing a PCSK9-specific ARCUS nuclease, licensed from Precision, that enables insertion of a functional copy of the OTC gene.

Key Points: 
  • ECUR-506 is iECURE’s in vivo gene insertion program designed to treat neonatal onset Ornithine Transcarbamylase (OTC) deficiency utilizing a PCSK9-specific ARCUS nuclease, licensed from Precision, that enables insertion of a functional copy of the OTC gene.
  • The Fast Track designation is designed to facilitate the development and expedite the review of therapeutics to treat serious conditions that fill an unmet medical need.
  • Provided relevant criteria are met, programs with Fast Track designation are eligible for accelerated approval and priority review as well.
  • “Congratulations to iECURE for this significant regulatory designation and for what it can potentially mean to patients with neonatal onset OTC deficiency.

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024

Retrieved on: 
Mittwoch, Mai 1, 2024
Technology, Biotechnology, Nanotechnology, Health, Other Health, Pharmaceutical, Stem Cells, Oncology, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, Congress, CTA, EASL, Gene editing, IND, Entrepreneurship, CccDNA, Precision BioSciences, Precision, HBV

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that the company will present late-breaking preclinical data from its clinical candidate, PBGENE-HBV, for the treatment of chronic hepatitis B (HBV) during a poster presentation at the European Association for Study of the Liver (EASL) Congress 2024 being held June 5-8, 2024 in Milan, Italy.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that the company will present late-breaking preclinical data from its clinical candidate, PBGENE-HBV, for the treatment of chronic hepatitis B (HBV) during a poster presentation at the European Association for Study of the Liver (EASL) Congress 2024 being held June 5-8, 2024 in Milan, Italy.
  • “We look forward to the opportunity to share the latest new preclinical safety data from our PBGENE-HBV clinical candidate at the EASL Congress,” said Jeff Smith, Co-Founder and Chief Research Officer at Precision BioSciences.
  • PBGENE-HBV is designed to safely eliminate cccDNA and inactivate integrated HBV DNA.
  • As we look ahead, we remain on track to file an investigational new drug (IND) and/or clinical trial application (CTA) in 2024.”
    Presenter: Emily Harrison, Senior Scientist - Hepatitis Research Leader, Precision Biosciences

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

Retrieved on: 
Dienstag, April 16, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, CTA, CRISPR, PMM, OTC, Gene editing, Partnership, Doctor of Philosophy, DMD, Prevail, Webcast, IND, Entrepreneurship, Novartis, DNA, Precision BioSciences, GLP, Eli Lilly and Company, CTAS, Toxicology, ID, Therapy, Precision, HBV, Vaccine

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.
  • Precision exercised its option to regain rights for the programs following Prevail Therapeutics’ decision to conclude the collaboration.
  • The collaboration began in January 2021 and was amended in June 2023 to transfer certain preclinical research, manufacturing, and investigational new drug (IND)-enabling activities from Precision BioSciences to Prevail Therapeutics.
  • “We enjoyed a productive gene editing collaboration with Prevail Therapeutics and appreciate their contributions to the success of these programs.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Mittwoch, März 27, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, Janus, Vivo, Gene editing, Precision BioSciences, Patient, Cash, Mitochondrion, Health care, Infant, NHP, IND, Duchenne muscular dystrophy, Investment, Therapy, ATM, Lilly, Precision, Cell, Skeletal muscle, Hepatitis B, Rachel Haurwitz, Central nervous system, Novartis, Primate, RNA, DNA, Mitochondrial disease, Hepatology, CRISPR, Safety, VWAP, PMM, Food, AAV, Development, Prevail, Publishing, Gene, ASX, University, Diaphragm, OTC, Hemoglobinopathy, IMU, Economics, Administration, Sickle cell disease, PCSK9, CTA, MHRA, Reindeer, Heart, Autoimmune disease, Eli Lilly and Company, DMD

PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.

Key Points: 
  • PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.
  • In November 2023, Precision presented preclinical efficacy and safety data at the 2023 American Association for the Study of Liver Diseases Annual Meeting.
  • Cash and Cash Equivalents: As of December 31, 2023, Precision had $116.7 million in cash and cash equivalents.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $7.0 million, as compared to $10.6 million for the quarter ended December 31, 2022.

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024

Retrieved on: 
Mittwoch, März 20, 2024
Research, Other Health, General Health, Pharmaceutical, Infectious Diseases, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Stem Cells, Health, Other Science, Precision BioSciences, Gene editing

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the fourth quarter and fiscal year 2023 and provide a business update on March 27, 2024.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the fourth quarter and fiscal year 2023 and provide a business update on March 27, 2024.